BR0010478A - Vacina de célula total contendo antìgeno de staphyloccocus aureus - Google Patents

Vacina de célula total contendo antìgeno de staphyloccocus aureus

Info

Publication number
BR0010478A
BR0010478A BR0010478-7A BR0010478A BR0010478A BR 0010478 A BR0010478 A BR 0010478A BR 0010478 A BR0010478 A BR 0010478A BR 0010478 A BR0010478 A BR 0010478A
Authority
BR
Brazil
Prior art keywords
antigen
aureus
cell vaccine
type
total cell
Prior art date
Application number
BR0010478-7A
Other languages
English (en)
Inventor
Ali I Fattom
Original Assignee
Nabi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi filed Critical Nabi
Publication of BR0010478A publication Critical patent/BR0010478A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)

Abstract

"VACINA DE CéLULA TOTAL CONTENDO ANTìGENO DE STAPHYLOCCOCUS AUREUS". Um antígeno de S. aureus negativamente carregado contém <225>-hexosamina como um principal componente de carboidrato. As cepas de S. aureus que carregam o antígeno respondem por quase todas as cepas clinicamente significativas que não são cepas do Tipo 5 ou Tipo 8. O antígeno podem ser utilizado em combinação com o antígeno de polissacarídeo de S. aureus do Tipo 5 e com o antígeno de polissacarídeo de S. aureus do Tipo 8 a fim de proporcionar quase 100% de cobertura da infecção por S. aureus. O antígeno e os anticorpos ao antígeno são úteis em conjuntos e testes para diagnóstico de infecção por S. aureus. A vacina de célula total que contém o antígeno é particularmente útil no tratamento de mastite.
BR0010478-7A 1999-05-10 2000-05-10 Vacina de célula total contendo antìgeno de staphyloccocus aureus BR0010478A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/307,775 US6294177B1 (en) 1996-09-11 1999-05-10 Staphylococcus aureus antigen-containing whole cell vaccine
PCT/US2000/012589 WO2000067785A2 (en) 1999-05-10 2000-05-10 Staphyloccocus aureus antigen-containing whole cell vaccine

Publications (1)

Publication Number Publication Date
BR0010478A true BR0010478A (pt) 2002-05-21

Family

ID=23191126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010478-7A BR0010478A (pt) 1999-05-10 2000-05-10 Vacina de célula total contendo antìgeno de staphyloccocus aureus

Country Status (15)

Country Link
US (2) US6294177B1 (pt)
EP (1) EP1178824B1 (pt)
JP (1) JP2002544169A (pt)
AT (1) ATE337015T1 (pt)
AU (1) AU777218B2 (pt)
BR (1) BR0010478A (pt)
CA (1) CA2372633C (pt)
CY (1) CY1105744T1 (pt)
DE (1) DE60030274T2 (pt)
DK (1) DK1178824T3 (pt)
ES (1) ES2270835T3 (pt)
MX (1) MXPA01011507A (pt)
NZ (1) NZ515394A (pt)
PT (1) PT1178824E (pt)
WO (1) WO2000067785A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US20030096315A1 (en) 2000-05-03 2003-05-22 Sanders Mitchell C. Device for detecting bacterial contamination and method of use
CN100359327C (zh) * 2001-06-15 2008-01-02 英希比泰克斯公司 识别凝血酶阴性的葡萄球菌和金黄色葡萄球菌的表面蛋白的交叉反应性单克隆抗体和多克隆抗体
CA2474458A1 (en) * 2002-01-31 2003-08-07 Mitchell C. Sanders Method for detecting microorganisms
WO2003067991A1 (en) 2002-02-13 2003-08-21 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
AU2003295520B8 (en) * 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
US20080085289A1 (en) 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
MX2007015758A (es) 2005-06-13 2008-02-22 Nabi Biopharmaceuticals Uso de leucocidina de panton-valentine para tratar y prevenir infecciones por estafilococos.
NZ570805A (en) * 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
US20090053235A1 (en) 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US20080170996A1 (en) * 2006-07-28 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and Methods for Stimulation of Lung Innate Immunity
EP2161035B1 (en) * 2007-05-28 2019-08-21 Daiichi Sankyo Company, Limited Bordetella parapertussis-containing whole-cell vaccine composition
BRPI0721892A2 (pt) * 2007-07-23 2014-05-13 Vaccine Res Internat Plc Composição de vacina, inalador, célula, métodos para vacinar um animal contra uma infecção bacteriana, para preparar uma linhagem de célula de hibridoma, e para preparar uma vacina para um patógeno bacteriano, usos de uma composição, de soros humanos, e de um anticorpo humano, linhagem de célula de hibridoma, anticorpo, fragmento de ligação ativo, soro, processo para a produção de uma vacina, e, cultura de célula bacteriana
KR20100072228A (ko) * 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2010011284A2 (en) 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
WO2010030790A2 (en) * 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
PT2411521E (pt) 2009-03-25 2015-04-21 Univ Texas Composições para estimulação de resistência imunitária inata de mamíferos contra patogénicos
LT3281947T (lt) 2009-04-03 2020-05-25 The University Of Chicago Kompozicijos ir būdai, susiję su baltymo a (spa) variantais
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX345967B (es) 2009-10-30 2017-02-28 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP3805395A1 (en) 2012-04-26 2021-04-14 University Of Chicago Staphylococcal coagulase antigens and methods of their use
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
BE1023004A1 (fr) 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
US11053532B2 (en) 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections
WO2019055620A1 (en) * 2017-09-13 2019-03-21 Stc. Unm SILICIFIED CELL REPLICAS, METHODS OF MANUFACTURE, AND METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3345864A1 (de) 1983-12-19 1985-06-27 Egbert Frh. von 8000 München Malsen-Ponickau Impfstoff und verfahren zu seiner herstellung
IN164864B (pt) 1985-05-13 1989-06-24 Commw Scient Ind Res Org
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine

Also Published As

Publication number Publication date
ES2270835T3 (es) 2007-04-16
CA2372633A1 (en) 2000-11-16
JP2002544169A (ja) 2002-12-24
PT1178824E (pt) 2007-01-31
AU4995000A (en) 2000-11-21
WO2000067785A2 (en) 2000-11-16
EP1178824A2 (en) 2002-02-13
CY1105744T1 (el) 2010-12-22
DE60030274D1 (de) 2006-10-05
WO2000067785A3 (en) 2001-02-08
MXPA01011507A (es) 2002-11-07
DE60030274T2 (de) 2008-01-10
NZ515394A (en) 2004-11-26
CA2372633C (en) 2010-03-30
US20020031528A1 (en) 2002-03-14
AU777218B2 (en) 2004-10-07
US6294177B1 (en) 2001-09-25
ATE337015T1 (de) 2006-09-15
US6537559B2 (en) 2003-03-25
DK1178824T3 (da) 2006-10-09
EP1178824B1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
BR0010478A (pt) Vacina de célula total contendo antìgeno de staphyloccocus aureus
BR0009157A (pt) Vacina e antìgeno de staphylococcus
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
BR0204142A (pt) Composição para a tintura das fibras queratìnicas humanas, processo de tintura direta e processo de tintura de oxidação das fibras queratìnicas humanas, dispositivo ou &#34;kit&#34; de tintura com vários compartimentos para a tintura das fibras queratìnicas humanas, compostos monoazóicos monocatiÈnicos e seu uso
BRPI9912227A (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
ATE414532T1 (de) Staphylococcus aureus antigen
BR0014512A (pt) Tratamento tópico para infecções por estreptococos
BR9912671A (pt) Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
BR0015592A (pt) Adesivo cheio com particulado orgânico, e, tira cosmética
TR200000695T2 (tr) Cildin durumunu iyileştirmek için bir yöntem.
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR9909026A (pt) Epìtopos nas proteìnas do envelope viral e anticorpos especìficos direcionados contra estes epìtopos; e uso para a detecção dos antìgenos virais do hcv no tecido do hospedeiro
BR9806171A (pt) Composição cosmética e/ou dermatológica e pronta para uso, processo para tintura e para tratamento das fibras de queratina e dispositivo ou &#39;kit&#39; de tintura de multi-compartimento
Conrad et al. Antibodies against the predominant glycosaminoglycan of the mammalian cornea, keratan sulfate-I.
BRPI0807601B8 (pt) método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
BR9713681A (pt) Artigo absorvente para ser utilizado por um usuário adjacente à pele
BR9806222A (pt) Composição cosmética e/ou dermatológica destinada ao tratamento das fibras queratìnicas, composição pronta para o uso, processo de tintura e de tratamento das fibras queratìnicas e dispositivos ou &#34;kit&#34; de tintura com vários compartimentos
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
Karrer et al. Primary anetoderma in children: report of two cases and literature review
BRPI0504500A (pt) uso de uma composição, composição cosmética, processo de tratamento das matérias queratìnicas e kit
BR9908443A (pt) Linhagens de células de medula espinhal humana e métodos para uso das mesmas
BR9612422A (pt) Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais.
BRPI0411944A (pt) anticorpos humanos especìficos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NABI BIOPHARMACEUTICALS (US)

Free format text: ALTERADO DE: NABI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: NABI BIOPHARMACEUTICALS (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020100119840/RJ DE 23/12/2010.

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE)

Free format text: TRANSFERIDO DE: NABI BIOPHARMACEUTICALS

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time